Bitcoin (BTC) needs to form a higher low above $75,500 to confirm support after its recent pullback, according to analyst Killa. Maintaining this support level, especially near $80,000, is crucial to keep the market structure similar to 2023 and to avoid further declines below $80,000. The current market pattern shows repeated breakout and breakdown signals, indicating a short-term liquidity battle. The next key step is confirmation of support to prevent an extended drop and enable another upward move.
Bitcoin's price structure is under scrutiny with a key support level at $75,500. For readers following cryptocurrency markets, here is Pluang's market snapshot as of Oct 13, 2026 20:51 WIB: out of 50 major cryptocurrencies, 7 rose and 42 fell today. Notable movers include ALGO at Rp2.150 down 5.83%, NEO at Rp42.834 down 5.69%, and XNO at Rp5.762 down 5.40%.
Domino's Pizza reported Q3 2026 earnings per share of $4.60, beating analyst expectations of $4.37, while revenue grew modestly by 3.4% to $1.19 billion. Same-store sales growth was minimal at 0.3% in the U.S. and 0.2% internationally, reflecting com...
Citigroup reported Q3 2026 earnings that exceeded analyst expectations, with EPS of $2.85 beating the $2.65 estimate and revenue of $23.8 billion slightly above forecasts. The bank's profit rose 40%, driven by exceptional fixed-income trading, invest...
State Street is set to report its Q3 2026 earnings with forecasts showing a 31.3% increase in earnings and 14% revenue growth, driven by strong net interest income and service fees. Despite record assets under management, higher operating and technol...
Restaurant Technologies, Inc. (RTI) released its 2026 Impact Report highlighting significant progress in sustainability and operational efficiency. In 2025, RTI recycled 393 million pounds of used cooking oil and delivered 719.4 million pounds of fre...
Over 60 companies are actively developing more than 65 medical marijuana therapies targeting conditions like chronic pain, neurological disorders, and cancer symptoms. Key drugs such as ZYN-002 and CardiolRx are in late-stage trials, with others in e...
